Johnson & Johnson reported strong sales growth and raised its full-year EPS guidance, reflecting confidence in cost-cutting measures and strategic investments. Despite some pressures from generic competition, the positive adjustments and shareholder-friendly actions like share repurchases suggest a favorable short-term outlook for the stock.

[1]